The U.S. Food and Drug Administration (FDA) has issued a statement outlining its plan to address concerns about the manufacture and sale of Schedule I drugs in the form of edible products that may be commonly consumed by minors. In a press release on June 16, 2022, the FDA outlined its plan of action to monitor the production of these products and other emerging cannabis-derived products of potential concern to the FDA.
The products of concern are widely known as copycat products, as they are packaged and labeled to look like popular children’s food brands. Their similarity to specific snacks that are marketed to children places minors at risk of accidental tetrahydrocannabinol, or THC, ingestion. Read below to learn more about the risks associated with copycat cannabis products and the FDA’s plan of action to combat their production.